Published online March 1, 2007
PEDIATRICS Vol. 119 Supplement March 2007, pp. S150-S162 (doi:10.1542/peds.2006-2023H)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Russell, R. G. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Russell, R. G. G.
Related Collections
Right arrow Therapeutics & Toxicology

SUPPLEMENT ARTICLE


Bisphosphonates: Mode of Action and Pharmacology

R. Graham G. Russell, MD, PhD

Botnar Research Centre and Oxford University Institute of Musculoskeletal Sciences, Oxford, United Kingdom

The profound effects of the bisphosphonates on calcium metabolism were discovered over 30 years ago, and they are now well established as the major drugs used for the treatment of bone diseases associated with excessive resorption. Their principal uses are for Paget disease of bone, myeloma, bone metastases, and osteoporosis in adults, but there has been increasing and successful application in pediatric bone diseases, notably osteogenesis imperfecta. Bisphosphonates are structural analogues of inorganic pyrophosphate but are resistant to enzymatic and chemical breakdown. Bisphosphonates inhibit bone resorption by selective adsorption to mineral surfaces and subsequent internalization by bone-resorbing osteoclasts where they interfere with various biochemical processes. The simpler, non–nitrogen-containing bisphosphonates (eg, clodronate and etidronate) can be metabolically incorporated into nonhydrolysable analogues of adenosine triphosphate (ATP) that may inhibit ATP-dependent intracellular enzymes. In contrast, the more potent, nitrogen-containing bisphosphonates (eg, pamidronate, alendronate, risedronate, ibandronate, and zoledronate) inhibit a key enzyme, farnesyl pyrophosphate synthase, in the mevalonate pathway, thereby preventing the biosynthesis of isoprenoid compounds that are essential for the posttranslational modification of small guanosine triphosphate (GTP)-binding proteins (which are also GTPases) such as Rab, Rho, and Rac. The inhibition of protein prenylation and the disruption of the function of these key regulatory proteins explains the loss of osteoclast activity. The recently elucidated crystal structure of farnesyl diphosphate reveals how bisphosphonates bind to and inhibit at the active site via their critical nitrogen atoms. Although bisphosphonates are now established as an important class of drugs for the treatment of many bone diseases, there is new knowledge about how they work and the subtle but potentially important differences that exist between individual bisphosphonates. Understanding these may help to explain differences in potency, onset and duration of action, and clinical effectiveness.

Key Words: bone resorption • osteoclasts • bisphosphonates • osteoporosis

Abbreviations: PPi—inorganic pyrophosphate • ATP—adenosine triphosphate • FPP—farnesyl diphosphate • GGPP—geranylgeranyl diphosphate • FPPS—farnesyl pyrophosphate synthase

Accepted Oct 5, 2006.




This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
J. Yan, S. Chen, Y. Zhang, X. Li, Y. Li, X. Wu, J. Yuan, A. G. Robling, R. Karpur, R. J. Chan, et al.
Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1
Hum. Mol. Genet., April 1, 2008; 17(7): 936 - 948.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
P. J. Mellor, S. Haugland, K. C. Smith, R. M. Powell, J. Archer, T. J. Scase, E. J. Villiers, P. E. McNeil, C. Nixon, C. Knott, et al.
Histopathologic, Immunohistochemical, and Cytologic Analysis of Feline Myeloma-Related Disorders: Further Evidence for Primary Extramedullary Development in the Cat
Vet. Pathol., March 1, 2008; 45(2): 159 - 173.
[Abstract] [Full Text] [PDF]

Home page
 J. Dent. Res.Home page
D.B. Kimmel
Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates
J. Dent. Res., November 1, 2007; 86(11): 1022 - 1033.
[Abstract] [Full Text] [PDF]